BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 25563425)

  • 1. Novel therapeutic options for relapsed hairy cell leukemia.
    Jain P; Polliack A; Ravandi F
    Leuk Lymphoma; 2015; 56(8):2264-72. PubMed ID: 25563425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on the biology and treatment options for hairy cell leukemia.
    Jain P; Pemmaraju N; Ravandi F
    Curr Treat Options Oncol; 2014 Jun; 15(2):187-209. PubMed ID: 24652320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors.
    Falini B; De Carolis L; Tiacci E
    Blood; 2022 Apr; 139(15):2294-2305. PubMed ID: 35143639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refractory and relapsed hairy-cell leukemia (HCL): casting light on promising experimental drugs in clinical trials.
    Robak T; Robak P
    Expert Opin Investig Drugs; 2023 Apr; 32(4):311-324. PubMed ID: 36931901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hairy Cell Leukemia (HCL) and HCL Variant: Updates and Spotlights on Therapeutic Advances.
    Paillassa J; Maitre E; Troussard X
    Curr Oncol Rep; 2022 Sep; 24(9):1133-1143. PubMed ID: 35403971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hairy cell leukemia: present and future directions.
    Kreitman RJ
    Leuk Lymphoma; 2019 Dec; 60(12):2869-2879. PubMed ID: 31068044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.
    Paillassa J; Safa F; Troussard X
    Ther Adv Hematol; 2022; 13():20406207221090886. PubMed ID: 35450208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoconjugates in the management of hairy cell leukemia.
    Kreitman RJ; Pastan I
    Best Pract Res Clin Haematol; 2015 Dec; 28(4):236-45. PubMed ID: 26614902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of hairy cell leukemia.
    Chihara D; Kreitman RJ
    Expert Rev Hematol; 2020 Oct; 13(10):1107-1117. PubMed ID: 32893700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hairy cell leukemia: update and current therapeutic approach.
    Salam L; Abdel-Wahab O
    Curr Opin Hematol; 2015 Jul; 22(4):355-61. PubMed ID: 26049757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How I manage patients with hairy cell leukaemia.
    Thompson PA; Ravandi F
    Br J Haematol; 2017 May; 177(4):543-556. PubMed ID: 28146266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New treatment options in hairy cell leukemia with focus on BRAF inhibitors.
    Falini B; Tiacci E
    Hematol Oncol; 2019 Jun; 37 Suppl 1():30-37. PubMed ID: 31187521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant.
    King AC; Kabel CC; Pappacena JJ; Stump SE; Daley RJ
    Ann Pharmacother; 2019 Sep; 53(9):922-932. PubMed ID: 30841702
    [No Abstract]   [Full Text] [Related]  

  • 14. Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia.
    Kreitman RJ; Pastan I
    Oncologist; 2020 Jan; 25(1):e170-e177. PubMed ID: 31628266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF in the cross-hairs.
    Geyer MB; Abdel-Wahab O; Tallman MS
    Expert Rev Hematol; 2019 Mar; 12(3):183-193. PubMed ID: 30782032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moxetumomab pasudotox for the treatment of hairy cell leukemia.
    Janus A; Robak T
    Expert Opin Biol Ther; 2019 Jun; 19(6):501-508. PubMed ID: 31045462
    [No Abstract]   [Full Text] [Related]  

  • 17. Hairy cell leukemia 2022: Update on diagnosis, risk-stratification, and treatment.
    Troussard X; MaƮtre E; Cornet E
    Am J Hematol; 2022 Feb; 97(2):226-236. PubMed ID: 34710243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Recombinant Immunotoxins for Hairy Cell Leukemia.
    Kreitman RJ; Pastan I
    Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32756468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential breakthroughs with investigational drugs for hairy cell leukemia.
    Robak T; Wolska A; Robak P
    Expert Opin Investig Drugs; 2015; 24(11):1419-31. PubMed ID: 26329588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.
    Sivina M; Kreitman RJ; Arons E; Ravandi F; Burger JA
    Br J Haematol; 2014 Jul; 166(2):177-88. PubMed ID: 24697238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.